Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Codrin Lungu

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Movement Disorders Clinical Practice|December 16, 2022
Comparison of Ultrasound and Electrical Stimulation Guidance for Onabotulinum Toxin-A Injections: A Randomized Crossover StudyCodrin Lungu, Alexandra Nmashie, Mary Catherine George, et al.
Neurology. Clinical Practice|March 3, 2023
Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 TrialsDaniel G Di Luca, Eric A Macklin, Karen Hodgeman, et al.
Neurology|February 15, 2013
Octanoic acid in alcohol-responsive essential tremor: a randomized controlled studyDietrich Haubenberger, Gayle McCrossin, Codrin Lungu, et al.
Frontiers in Neurology|May 19, 2017
Research Priorities in Limb and Task-Specific DystoniasSarah Pirio Richardson, Eckart Altenmüller, Katharine Alter, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 31, 2019
Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's diseaseJohn D Heiss, Codrin Lungu, Dima A Hammoud, et al.
Neurology|February 27, 2020
Defining research priorities in dystoniaCodrin Lungu, Laurie Ozelius, David Standaert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 8, 2024
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's DiseaseJohn D Heiss, Abhik Ray-Chaudhury, David E Kleiner, et al.
Parkinsonism & Related Disorders|September 25, 2021
Seeking progress in disease modification in Parkinson diseaseCodrin Lungu, Jesse M Cedarbaum, Ted M Dawson, et al.
Biomarkers in Medicine|June 24, 2017
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers ProgramKatrina Gwinn, Karen K David, Christine Swanson-Fischer, et al.
Annals of Clinical and Translational Neurology|December 22, 2020
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)Ruth B Schneider, Larsson Omberg, Eric A Macklin, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Movement Disorders Clinical Practice|December 16, 2022
Comparison of Ultrasound and Electrical Stimulation Guidance for Onabotulinum Toxin-A Injections: A Randomized Crossover StudyCodrin Lungu, Alexandra Nmashie, Mary Catherine George, et al.
Neurology. Clinical Practice|March 3, 2023
Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 TrialsDaniel G Di Luca, Eric A Macklin, Karen Hodgeman, et al.
Neurology|February 15, 2013
Octanoic acid in alcohol-responsive essential tremor: a randomized controlled studyDietrich Haubenberger, Gayle McCrossin, Codrin Lungu, et al.
Frontiers in Neurology|May 19, 2017
Research Priorities in Limb and Task-Specific DystoniasSarah Pirio Richardson, Eckart Altenmüller, Katharine Alter, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 31, 2019
Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's diseaseJohn D Heiss, Codrin Lungu, Dima A Hammoud, et al.
Neurology|February 27, 2020
Defining research priorities in dystoniaCodrin Lungu, Laurie Ozelius, David Standaert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 8, 2024
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's DiseaseJohn D Heiss, Abhik Ray-Chaudhury, David E Kleiner, et al.
Parkinsonism & Related Disorders|September 25, 2021
Seeking progress in disease modification in Parkinson diseaseCodrin Lungu, Jesse M Cedarbaum, Ted M Dawson, et al.
Biomarkers in Medicine|June 24, 2017
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers ProgramKatrina Gwinn, Karen K David, Christine Swanson-Fischer, et al.
Annals of Clinical and Translational Neurology|December 22, 2020
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)Ruth B Schneider, Larsson Omberg, Eric A Macklin, et al.
Pageof 6